timothy sykes logo

Stock News

Veracyte Stock Soars Amid Strong Earnings and New Price Targets

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Tim Sykes Fact-checked by Matt Monaco
Updated 11/23/2025, 11:17 am ET 11/23/2025, 11:17 am ET | 6 min 6 min read
Veracyte Stock Soars Amid Strong Earnings and New Price Targets Thumbnail

Veracyte Inc. stock has been trading up by 9.89 percent, driven by significant market excitement and positive sentiment.

Healthcare industry expert:

Analyst sentiment – positive

Veracyte, Inc. (VCYT) maintains a compelling market position characterized by strong gross margins at 68.5% and a reasonable EBITDA margin of 10.8%. However, its pre-tax profit margins are negative, at -8.6%, indicating room for improvement in cost control or pricing strategy. With revenues amounting to $445.8M, showing consistent growth over three and five-year periods at 20.42% and 34.46% respectively, the company demonstrates its ability to generate top-line growth. Their financial strength is characterized by low debt levels, with a total debt-to-equity ratio of 0.03 and a robust current ratio of 6.2, underscoring a stable financial footing. Despite a high P/E ratio of 112.85, reflecting growth potential rather than intrinsic value, their profitability has improved, as indicated by heightened interest from investors and analysts.

Technically, VCYT exhibits a bullish trend accentuated by a significant price advance from $39.28 to $44.89 within a week, indicative of strong upward momentum supported by robust volume patterns. The consistent increasing lows and highs form a bullish continuation pattern, suggesting potential for further ascendance. Traders should consider entering long positions on any pullback to the $40.50 level, which serves as a critical support. Anticipate resistance near $45 guided by recent trading action, and position stop losses below $38.70 to manage downside risks. This strategy aligns with the positive fundamental signals that support sustained upward movement.

Veracyte’s strategic positioning is bolstered by recent developments, such as the inclusion of their Decipher prostate test in the NCCN guidelines, which offers substantial revenue upside through new market penetration. The company’s Q3 results, surpassing expectations with an adjusted EPS of $0.51 against a consensus of $0.32 and beating revenue forecasts, reflects effective operational execution. Furthermore, the firm’s elevation of FY25 revenue forecast enhances investor confidence in VCYT’s growth trajectory. Analysts’ upward revisions of price targets further affirm a positive outlook. While recent positive price movements indicate strong investor sentiment buoyed by strategic advancements, potential near-term resistance levels appear around $48, as per UBS and Canaccord guidance. Overall, Veracyte’s strategic execution and enhanced market acceptance of their diagnostic tests suggest continued growth, reinforcing a positive sentiment.

Candlestick Chart

Weekly Update Nov 17 – Nov 21, 2025: On Sunday, November 23, 2025 Veracyte Inc. stock [NASDAQ: VCYT] is trending up by 9.89%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Veracyte’s recent financial disclosure highlights a strong performance. The company reported a Q3 revenue of $131.9M, exceeding Wall Street forecasts of $124.85M. This performance contributed to an EPS of $0.51, well above the anticipated $0.32. Such figures underscore Veracyte’s growing market footprint and operational effectiveness.

Examining financial ratios reveals a healthy gross margin of 68.5%, which suggests efficient production and service delivery practices. The EBIT margin stands at 6.3%, while EBITDA margin registers at 10.8%, both pointing to a sustainable profit structure. However, the pre-tax profit margin displayed negative at -8.6%, indicating challenges still to be resolved in maintaining profitability.

Further support for the company’s robust performance comes from its revenue growth – 20.42% over three years and 34.46% over five years. The company’s total debt-to-equity ratio is impressively low at 0.03, implying financial stability with ample capacity for future investments. Analysts have adjusted price targets upward, reflecting increased confidence in future growth prospects. The raised FY25 revenue forecast between $506M and $510M further illustrates this optimistic sentiment.

Stock price trends have also reflected positive news with recent price movements showcasing a significant uptick. Over the past sessions, prices opened at $39.28, moving steadily to a close of $44.89, marking a consistent upward trend. Summing these metrics paints a promising picture for Veracyte, as both operational efficiency and market enthusiasms appear to align.

More Breaking News

Conclusion

The overall market sentiment for Veracyte is decidedly positive, driven by excellent quarterly results and strategic upward guidance adjustments. With an elevation in stock price targets and strong back-end numbers, the momentum for Veracyte has gained notable traction.

Trader confidence is likely to remain buoyant, attributed to the updated NCCN guidelines and broadened technological application in critical domains. As millionaire penny stock trader and teacher Tim Sykes says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.” This mindset underscores a crucial aspect of trading with Veracyte, as the path forward looks optimistic. The decisive financial position augurs well for sustaining growth trajectories, and as these developments unfold, Veracyte can potentially continue to fortify its market standing and financial metrics, promising ample rewards for stakeholders attuned to its growth narrative.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”